Senthil Selvaraj

Nov 8, 2024 | onlinelibrary.wiley.com | John W. Ostrominski |Petar Seferovic |Serbian Academy |Senthil Selvaraj

Corresponding Author Senthil Selvaraj Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA Duke Molecular Physiology Institute, Durham, NC, USA Corresponding author. Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N Duke St, Durham, NC 27701, USA. Email: [email protected] for more papers by this author

May 12, 2024 | jamanetwork.com | Senthil Selvaraj |Brian Claggett |Robert J. Mentz |Michel G. Khouri

Key PointsQuestion  What is the natural history and cardiovascular burden of the V142I variant of the transthyretin (TTR) gene among US Black carriers across mid to late life? Findings  Across 4 cohort studies, carriers (754/23 338) faced a substantially increased risk for heart failure (by age 63 years) and death (by age 72 years), similarly in men and women, which was estimated to contribute to approximately 1 million years of life lost among US Black individuals aged ≥50 years.

Oct 13, 2023 | ahajournals.org | John W. Ostrominski |Muthiah Vaduganathan |Senthil Selvaraj |Brian Claggett

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population.